

COVID-19 vaccination after stem cell or bone marrow transplant

Introduction

NHS England has been working with the British Society of Blood and Marrow Transplantation and Cellular Therapy and Anthony Nolan to ensure that those who have received a stem cell transplant or CAR-T therapy are offered COVID-19 re-vaccination. In patients who receive stem cell transplants or CAR-T therapy, any protective antibodies from exposure or vaccination prior to transplantation are likely to be lost and it is unclear whether the recipient acquires the donor's immunity.

Any previous COVID-19 vaccination is to be discounted and it is recommended that the individual is re-vaccinated as if they have never received a COVID-19 vaccine. They are likely to require re-vaccination with other vaccines too (Green Book Chapter 7)¹.

In COVID-19: the green book, chapter 14a², the Joint Committee on Vaccination and Immunisation (JCVI) has advised that ***'individuals who have received a bone marrow transplant after vaccination should be considered for a re-immunisation programme for all routine vaccinations and for COVID-19'***.

The British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) has prepared statements on vaccination and re-vaccination of HSCT and CAR-T patients, available at bsbmtct.org/bsbmtct-and-covid/

In summary

- HSCT and CAR-T recipients who have received prior doses of a SARS-CoV-2 vaccine pre-procedure should be considered never-vaccinated in keeping with Green Book guidance and offered full re-vaccination with a SARS-CoV-2 vaccine course.
- The JCVI has advised that individuals aged 12+ who were immunosuppressed at the time of their primary doses including those who have received a stem cell transplant in the previous 24 months should receive a three-dose SARS-CoV-2 primary schedule. In addition, further booster doses are now being offered to this group.
- For children aged 5-11 who are severely immunosuppressed the advice is for three primary and booster doses at a reduced paediatric dose of the Pfizer-BioNTech (Comirnaty[®]) vaccine.
- The BSBMTCT recommends vaccination or re-vaccination from 3-6 months post autologous HSCT, allogeneic HSCT and CAR-T therapy. This applies to both adult and paediatric patients.

Annex A is a draft letter which can be used to inform a patient's registered general practitioner regarding the vaccination requirement. It is recommended that a copy of the letter is also sent to the patient as per normal practice.

1. Public Health England. [Immunisation of individuals with underlying medical conditions: the green book, chapter 7](#) (2020).

2. Public Health England. [Immunisation against Infectious Disease; chapter 14a](#) (2022).

Dear

Important information reference – COVID-19 vaccination for:

Patient's name:

DOB:

NHS number:

I am writing to inform you that the patient named above has received a haematopoietic stem cell transplant (HSCT) or CAR-T therapy.

In COVID-19: The Green Book, chapter 14a, the Joint Committee on Vaccination and Immunisation (JCVI) has advised that “individuals who receive bone marrow transplants, and many individuals who receive CAR-T therapy for certain conditions, should be considered for a full course of revaccination for all vaccines used in the routine programme”.

The British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) has prepared statements on vaccination and re-vaccination of HSCT and CAR-T patients, available at bsbmtct.org/bsbmtct-and-covid/

This patient's transplant team has assessed that this patient is suitable for re-vaccination with the full primary and booster dose schedule of a SARS-CoV-2 vaccine.

The BSBMTCT recommends vaccination or re-vaccination from 3-6 months post-HSCT and CAR-T.

Please see the note overleaf for practical guidance from NHS England on how to arrange and record re-vaccination after transplant.

If you need any further information or guidance please don't hesitate to contact this patient's transplant team using the details below.

Yours sincerely,

Note on re-vaccination in practice

This can be done using any age-appropriate vaccine following JCVI guidelines or as appropriate following specialist opinion on which vaccine maybe more appropriate. Details of repeated doses should be added using the standard point of care software and the record annotated to show that this is an intentional duplication following stem cell transplantation.

Timing of vaccination will be determined by the specialist but would normally be with first dose 12 to 24 weeks post HSCT or CAR-T, the second dose following 8 to 12 weeks later, and a third dose 8 weeks after the second. Further booster doses to be no earlier than 12 weeks after the previous dose. Accelerated dosing earlier than 8 weeks is not normally indicated.

Payment where relevant to the providing service should follow the re-vaccination, following local protocols and procedures.

Re-vaccination will not impact upon COVID Pass processes, where the individual had already been issued with a pass.

Further reading:

1. Public Health England.

[Immunisation of individuals with underlying medical conditions: the green book, chapter 7 \(2020\).](#)

2. Public Health England.

[Immunisation against Infectious Disease; chapter 14a \(2022\).](#)